Orientation guide for industry - EMA building
Submitted by Anonymous (not verified) on 16 June 2025 - 15:29
Orientation guide for industry - EMA building
Orientation guide for patient representatives and healthcare professionals - EMA building
Submitted by Anonymous (not verified) on 16 June 2025 - 15:28
Orientation guide for patient representatives and healthcare professionals - EMA building
Orientation guide for delegates - EMA building
Submitted by Anonymous (not verified) on 16 June 2025 - 15:27
Orientation guide for delegates - EMA building
Agenda - Workshop on the use of Bayesian statistics in clinical development
Submitted by Anonymous (not verified) on 16 June 2025 - 15:03
Agenda - Workshop on the use of Bayesian statistics in clinical development
Allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations - Scientific guideline
Submitted by Anonymous (not verified) on 16 June 2025 - 14:57
Allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations - Scientific guideline
EMEA-002724-PIP01-19-M03
Submitted by Anonymous (not verified) on 16 June 2025 - 14:37
EMEA-002724-PIP01-19-M03
Annex to 16-19 June 2025 CHMP Agenda
Submitted by Anonymous (not verified) on 16 June 2025 - 14:31
Annex to 16-19 June 2025 CHMP Agenda
Agenda of the CHMP meeting 16-19 June 2025
Submitted by Anonymous (not verified) on 16 June 2025 - 14:30
Agenda of the CHMP meeting 16-19 June 2025
HMA-EMA joint Network Data Steering Group meeting - 30 April 2025
Submitted by Anonymous (not verified) on 16 June 2025 - 14:21
HMA-EMA joint Network Data Steering Group meeting - 30 April 2025
Opinion/decision on a Paediatric investigation plan (PIP): Zynlonta, Loncastuximab tesirine, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: P/0152/2024
Submitted by Anonymous (not verified) on 16 June 2025 - 13:29
Opinion/decision on a Paediatric investigation plan (PIP): Zynlonta, Loncastuximab tesirine, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: P/0152/2024